AKASHI THERAPEUTICS
Akashi Therapeutics formerly known as Dart Therapeutics Inc. Akashi Therapeutics is a clinical stage biopharmaceutical company. Our mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition.
AKASHI THERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Therapeutics
Founded:
2012-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.akashirx.com
Total Employee:
1+
Status:
Active
Contact:
617-431-7250
Total Funding:
1.5 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API WordPress LetsEncrypt SSL By Default Font Awesome
Similar Organizations
MiNK Therapeutics
MiNK Therapeutics provides Living drugs, Adoptive Cell Therapy, and T Cell Receptors (TCRs).
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
BioCardia
BioCardia is a clinical-stage regenerative medicine company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Cerebral Therapeutics
Cerebral Therapeutics is a clinical-stage pharmaceutical company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
GENFIT
GENFIT is a late-stage biopharmaceutical company.
Mahzi Therapeutics
Mahzi Therapeutics is a health care and biotechnology company.
Caraway Therapeutics
Rheostat Therapeutics is a bio therapeutics company.
Transcode Therapeutics
TransCode Therapeutics is a pre-clinical biopharmaceutical company.
Current Employees Featured
Marc B. Blaustein CEO & Founder @ Akashi Therapeutics
CEO & Founder
Benjamin Seckler Founder @ Akashi Therapeutics
Founder
Ernest D. Bush CSO @ Akashi Therapeutics
CSO
Founder
Official Site Inspections
http://www.akashirx.com
- Host name: sv89.ifastnet.com
- IP address: 82.163.176.101
- Location: United Kingdom
- Latitude: 51.4964
- Longitude: -0.1224
- Timezone: Europe/London
More informations about "Akashi Therapeutics"
About Us - Akashi RX
The Name. Sixty years ago in the perilous waters of Japan’s Akashi Strait, two ferry boats collided and sank, killing 168 children. Public outcry over the tragedy inspired the government to …See details»
Akashi RX
Company Overview. Akashi Therapeutics is a clinical stage biopharmaceutical company. Our mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric …See details»
Board of Directors - Akashi RX
Tracy Seckler. Charley’s Fund Tracy, along with her husband Benjamin Seckler, M.D., established Charley’s fund in 2004. Charley’s fund is a dynamic foundation focused on supporting the …See details»
Akashi Therapeutics Company Profile | Management and
Www.akashirx.com . Contact Information. Headquarters. 245 1st St Fl 18, Cambridge, Massachusetts, 02142, United States (617) 431-7250. Akashi Therapeutics Profile and History …See details»
Akashi Therapeutics Inc - Drug pipelines, Patents, Clinical trials ...
Www.akashirx.com. Private Company | 2012 | Massachusetts, United States | < 10 | www.akashirx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. Translational …See details»
Akashi Therapeutics - VentureRadar
Website: http://www.akashirx.com. Develops treatments for Duchenne muscular dystrophy and other rare pediatric diseases, aiming to transform Duchenne into a ...See details»
Akashi Therapeutics, Inc. Overview | SignalHire Company Profile
Phone Number: 1-617-431-7250: Akashi Therapeutics,... industries Biotech, Pharmaceuticals: Headquarters LocationSee details»
Akashi Therapeutics - Overview, News & Similar companies
Who is Akashi Therapeutics. Akashi Therapeutics is a clinical stage biopharmaceutical company whose mission is to develop treatments for Duchenne muscular dystrophy and other rare …See details»
Akashi Therapeutics Inc Overview - Salary.com
Discover essential details about Akashi Therapeutics Inc, including address, contact, and journey of our company's evolution.See details»
Our Team - Akashi RX
Each member of Akashi’s executive team is a highly accomplished leader in his or her respective field. Senior members of the team have several decades of executive-level experience in …See details»
akashirx.com Reviews | check if site is scam or legit| Scamadviser
Check akashirx.com with our free review tool and find out if akashirx.com is legit and reliable. Need advice? Report scams Check Scamadviser! Report a Scam Help & Info API & Data …See details»
Akashi Therapeutics, Inc. - Company Profile & Staff Directory
Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. The lead clinical asset is HT-100, …See details»
Akashi’s Competitors, Revenue, Number of Employees, Funding
Akashi’s Profile, Revenue and Employees. Akashi Therapeutics is a biopharmaceutical company develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. …See details»
Scientific Advisory Board - Akashi RX
“The interaction between Akashi and the patient community is much greater than you will find at pharma R&D; organizations. I believe this degree of closeness and overlap between the …See details»
Akashi Therapeutics - Craft
Akashi Therapeutics has 5 employees at their 1 location and $1.5 m in total funding,. See insights on Akashi Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
HT-100: A Drug To Treat Fibrosis And Inflammation - Duchenne UK
Nov 3, 2016 Registered Charity No. 1147094 A non profit company limited by guarantee. Registered in England No. 8030768See details»
Dosing and Enrollment in HT-100 Trial in Patients with DMD …
Press Release: Dosing and Enrollment in HT-100 Trial Suspended Background: Akashi Therapeutics has reported that dosing and new patient enrollment in the phase 1b/2a HALO …See details»
Business Advisory Board - Akashi RX
Cristina Csimma, PharmD, MHP. Cristina Csimma’s experience in the biopharmaceutical, venture capital and academic settings encompasses global development in multiple therapeutic areas …See details»
aya ♡ (@akashirx) • Instagram photos and videos
0 Followers, 371 Following, 6 Posts - See Instagram photos and videos from aya ♡ (@akashirx)See details»
News - Akashi RX
Akashi is developing a pipeline of therapies with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. For more …See details»